BACKGROUND: Biomarkers of extracellular matrix remodeling are associated with prevalent hypertension in cross-sectional studies, but their relations to longitudinal changes in blood pressure (BP) and hypertension incidence are unknown. METHODS AND RESULTS: We evaluated 595 nonhypertensive Framingham Offspring Study participants (mean age 55 years; 360 women) without prior heart failure or myocardial infarction who underwent routine measurements of plasma tissue inhibitor of metalloproteinase-1 (TIMP-1), metalloproteinase-9 (MMP-9), and procollagen III N-terminal peptide. We related plasma TIMP-1, procollagen III N-terminal peptide, and MMP-9 to the incidence of hypertension and progression of BP by >or=1 category (defined on the basis of the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure). On follow-up (4 years), 81 participants (51 women) developed hypertension, and 198 (114 women) progressed to a higher BP category. In multivariable models, a 1-SD increment of log-TIMP-1 was associated with a 50% higher incidence of hypertension (95% CI 1.08 to 2.08) and a 21% (95% CI 1.00 to 1.47) higher risk of BP progression. Individuals in the top TIMP-1 tertile had a 2.15-fold increased risk of hypertension (95% CI 0.99 to 4.68) and 1.68-fold (95% CI 1.05 to 2.70) increased risk of BP progression relative to the lowest tertile. Individuals with detectable MMP-9 had a 1.97-fold higher risk of BP progression (95% CI 1.06 to 3.64) than those with undetectable levels. Plasma procollagen III N-terminal peptide was not associated with hypertension incidence or BP progression. CONCLUSIONS: In the present community-based sample, higher TIMP-1 and MMP-9 concentrations were associated with BP progression on follow-up. Additional studies are warranted to confirm our findings.
BACKGROUND: Biomarkers of extracellular matrix remodeling are associated with prevalent hypertension in cross-sectional studies, but their relations to longitudinal changes in blood pressure (BP) and hypertension incidence are unknown. METHODS AND RESULTS: We evaluated 595 nonhypertensive Framingham Offspring Study participants (mean age 55 years; 360 women) without prior heart failure or myocardial infarction who underwent routine measurements of plasma tissue inhibitor of metalloproteinase-1 (TIMP-1), metalloproteinase-9 (MMP-9), and procollagen III N-terminal peptide. We related plasma TIMP-1, procollagen III N-terminal peptide, and MMP-9 to the incidence of hypertension and progression of BP by >or=1 category (defined on the basis of the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure). On follow-up (4 years), 81 participants (51 women) developed hypertension, and 198 (114 women) progressed to a higher BP category. In multivariable models, a 1-SD increment of log-TIMP-1 was associated with a 50% higher incidence of hypertension (95% CI 1.08 to 2.08) and a 21% (95% CI 1.00 to 1.47) higher risk of BP progression. Individuals in the top TIMP-1 tertile had a 2.15-fold increased risk of hypertension (95% CI 0.99 to 4.68) and 1.68-fold (95% CI 1.05 to 2.70) increased risk of BP progression relative to the lowest tertile. Individuals with detectable MMP-9 had a 1.97-fold higher risk of BP progression (95% CI 1.06 to 3.64) than those with undetectable levels. Plasma procollagen III N-terminal peptide was not associated with hypertension incidence or BP progression. CONCLUSIONS: In the present community-based sample, higher TIMP-1 and MMP-9 concentrations were associated with BP progression on follow-up. Additional studies are warranted to confirm our findings.
Authors: Peter Mclean Timms; Ann Wright; Paul Maxwell; Stewart Campbell; Anne Beatrice Dawnay; Vinajur Srikanthan Journal: Am J Hypertens Date: 2002-03 Impact factor: 2.689
Authors: A Zervoudaki; E Economou; C Stefanadis; C Pitsavos; K Tsioufis; C Aggeli; K Vasiliadou; M Toutouza; P Toutouzas Journal: J Hum Hypertens Date: 2003-02 Impact factor: 3.012
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: Eric M Wilson; Himali R Gunasinghe; Mytsi L Coker; Philip Sprunger; Dorellyn Lee-Jackson; Biykem Bozkurt; Anita Deswal; Douglas L Mann; Francis G Spinale Journal: J Card Fail Date: 2002-12 Impact factor: 5.712
Authors: Michael R Zile; Stacia M Desantis; Catalin F Baicu; Robert E Stroud; Sheila B Thompson; Catherine D McClure; Shannon M Mehurg; Francis G Spinale Journal: Circ Heart Fail Date: 2011-02-24 Impact factor: 8.790
Authors: Raghava S Velagaleti; Philimon Gona; Johan Sundström; Martin G Larson; Deborah Siwik; Wilson S Colucci; Emelia J Benjamin; Ramachandran S Vasan Journal: Arterioscler Thromb Vasc Biol Date: 2010-08-26 Impact factor: 8.311
Authors: Isha Agarwal; Nicole L Glazer; Eddy Barasch; Mary L Biggs; Luc Djousse; Annette L Fitzpatrick; John S Gottdiener; Joachim H Ix; Jorge R Kizer; Eric B Rimm; David S Sicovick; Russell P Tracy; Kenneth J Mukamal Journal: Circ Arrhythm Electrophysiol Date: 2014-06-24